ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2014 to Q3 2025

Type / Class
Equity / Ordinary Shares, nominal value Euro 0.04 per share
Symbol
PRQR on Nasdaq
Shares outstanding
105,365,368
Price per share
$1.95
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
37,542,716
Total reported value
$79,967,112
% of total 13F portfolios
0%
Share change
-2,931,586
Value change
-$6,233,021
Number of holders
63
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VAN HERK INVESTMENTS B.V. 14% +7.7% $31,668,615 +$2,331,550 14,329,690 +7.9% Van Herk Investments B.V. 29 Sep 2025
Adage Capital Management, L.P. 6.3% -18% $13,467,954 -$3,060,326 6,601,938 -19% Adage Capital Management, L.P. 30 Jun 2025

As of 30 Sep 2025, 63 institutional investors reported holding 37,542,716 shares of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR). This represents 36% of the company’s total 105,365,368 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) together control 34% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ADAGE CAPITAL PARTNERS GP, L.L.C. 5.9% 6,253,467 -5.3% 0.02% $13,319,885
Privium Fund Management B.V. 4.7% 4,998,287 +0.01% 1.9% $10,646,351
Affinity Asset Advisors, LLC 3.4% 3,600,000 +2.9% 0.71% $7,668,000
MORGAN STANLEY 2.8% 2,901,202 -5.9% 0% $6,179,561
Aberdeen Group plc 2.2% 2,298,823 +24% 0.01% $4,896,493
Sio Capital Management, LLC 2% 2,075,139 0% 1.1% $4,420,046
Kynam Capital Management, LP 1.6% 1,649,462 0% 0.26% $3,513,354
DAFNA Capital Management LLC 1.5% 1,567,561 0% 0.82% $3,338,905
Siren, L.L.C. 1.5% 1,552,183 0% 0.13% $3,306,150
ArrowMark Colorado Holdings LLC 1.2% 1,246,234 +3.9% 0.05% $2,654,478
PLATINUM INVESTMENT MANAGEMENT LTD 1.2% 1,235,514 -15% 0.17% $2,631,645
M28 Capital Management LP 0.97% 1,019,498 0% 3.2% $2,171,531
Ikarian Capital, LLC 0.85% 892,229 +2.8% 0.43% $1,900,447
Point72 Asset Management, L.P. 0.71% 750,000 0% 0% $1,597,500
CITADEL ADVISORS LLC 0.62% 657,012 +73% 0% $1,399,436
MACQUARIE GROUP LTD 0.59% 620,000 0% 0% $1,321,000
Walleye Capital LLC 0.5% 531,977 0% 0.01% $1,133,111
Monaco Asset Management SAM 0.44% 460,000 0% 0.36% $979,800
TWO SIGMA INVESTMENTS, LP 0.4% 417,300 +86% 0% $888,849
NORTHERN TRUST CORP 0.28% 294,742 -25% 0% $627,801
BOOTHBAY FUND MANAGEMENT, LLC 0.24% 248,290 +11% 0.01% $528,858
MILLENNIUM MANAGEMENT LLC 0.23% 240,622 -82% 0% $512,525
TWO SIGMA ADVISERS, LP 0.22% 228,600 +63% 0% $486,918
Palo Alto Investors LP 0.18% 188,807 0.07% $402,159
DIADEMA PARTNERS LP 0.15% 157,694 0% 0.23% $335,888

Institutional Holders of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 37,542,716 $79,967,112 -$6,233,021 $2.13 63
2025 Q2 40,456,202 $82,379,793 -$1,567,785 $2.04 61
2025 Q1 41,291,570 $54,918,956 -$5,787,635 $1.33 63
2024 Q4 44,407,421 $117,680,021 +$75,460,221 $2.65 74
2024 Q3 17,443,866 $31,743,198 +$264,549 $1.82 45
2024 Q2 17,290,486 $28,649,850 -$212,174 $1.66 47
2024 Q1 17,387,392 $39,773,390 -$2,337,680 $2.29 48
2023 Q4 18,391,369 $36,955,484 -$454,962 $1.98 46
2023 Q3 18,716,181 $24,328,704 -$3,600,695 $1.30 45
2023 Q2 21,135,686 $34,237,327 -$2,196,851 $1.62 50
2023 Q1 22,322,571 $47,544,921 +$11,107,713 $2.13 54
2022 Q4 16,678,999 $59,949,585 -$4,474,620 $3.70 44
2022 Q3 21,236,882 $15,861,034 -$760,592 $0.74 42
2022 Q2 22,126,805 $17,208,344 -$8,963,813 $0.78 47
2022 Q1 31,740,344 $28,730,297 -$92,041,029 $0.91 56
2021 Q4 45,445,352 $364,779,631 +$6,635,516 $8.01 72
2021 Q3 39,831,678 $333,392,000 +$12,212,303 $8.37 65
2021 Q2 38,480,445 $259,361,000 -$31,879,222 $6.74 61
2021 Q1 43,321,891 $286,357,000 +$115,578,874 $6.61 63
2020 Q4 26,413,704 $110,936,100 -$6,602,420 $4.20 46
2020 Q3 19,690,795 $94,319,000 -$5,245,378 $4.79 21
2020 Q2 29,107,854 $176,974,000 -$802,484 $6.08 43
2020 Q1 29,335,757 $161,049,000 -$7,183,294 $5.49 43
2019 Q4 30,150,188 $298,791,000 +$87,234,363 $9.91 51
2019 Q3 21,662,331 $124,772,000 -$19,145,910 $5.76 49
2019 Q2 23,626,883 $215,004,000 -$8,675,469 $9.10 55
2019 Q1 24,000,014 $332,879,291 +$6,357,080 $13.87 54
2018 Q4 23,104,591 $364,447,000 +$50,602,846 $15.78 57
2018 Q3 19,515,607 $377,636,000 +$168,574,699 $19.35 35
2018 Q2 11,069,586 $80,808,000 +$5,443,350 $7.30 24
2018 Q1 10,687,432 $32,865,000 -$2,756,918 $3.08 23
2017 Q4 11,508,113 $37,112,000 +$4,385,460 $3.22 26
2017 Q3 10,077,120 $48,873,000 +$5,139,062 $4.85 22
2017 Q2 9,002,972 $46,815,000 +$1,971,549 $5.20 17
2017 Q1 9,010,116 $45,050,000 +$634,080 $5.00 20
2016 Q4 8,889,119 $43,557,000 +$395,680 $4.90 22
2016 Q3 8,692,509 $57,980,000 -$2,944,700 $6.67 25
2016 Q2 9,151,395 $44,281,000 -$2,331,016 $4.84 26
2016 Q1 9,632,100 $46,949,000 -$10,777,157 $4.88 29
2015 Q4 11,189,723 $97,062,000 -$3,472,581 $8.68 32
2015 Q3 11,137,806 $162,244,000 +$3,974,891 $14.57 35
2015 Q2 10,835,771 $180,597,000 -$5,671,266 $16.67 36
2015 Q1 11,013,755 $241,353,000 +$65,737,809 $21.88 38
2014 Q4 8,018,201 $172,936,000 +$8,842,888 $21.67 35
2014 Q3 7,627,734 $129,886,000 +$129,886,000 $17.19 30